Introduction {#s1}
============

Head and neck cancer (HNC) is a type of cancer within the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. As the sixth most common cancer and ninth most frequent cause of cancer-related death, HNC affected more than 4.6 million people worldwide in 2013, and it has a high morbidity and a low survival rate (Petersen, [@B33]; Brunotto et al., [@B5]; Chai et al., [@B9]; Global Burden of Disease Study 2013 Collaborators, [@B14]). Incidence of HNC is increasing worldwide and according to the World Health Organization (WHO) this trend is expected to continue into the next several decades (Bettendorf et al., [@B3]). HNC occurs most often in men in their 50s or 60s, but in recent years the incidence among younger individuals has increased (Bray et al., [@B4]). It has been shown that smoking, alcohol consumption, viral infection with Epstein-Barr virus (EBV) or human papillomavirus (HPV), and environmental exposure are the primary etiologic factors contributing to HNC. Likewise, genetic susceptibility also plays a critical role in the development of HNC (Brunotto et al., [@B5]; Lacko et al., [@B20]; Munshi et al., [@B30]).

As the most common form of genetic variation in humans, single nucleotide polymorphism (SNP) in genes encoding for susceptibility factors may influence gene expression, protein function, and disease predisposition (Nachman, [@B31]; Hsu et al., [@B16]). Many studies have shown that SNPs in some genes may contribute to an individual\'s susceptibility to cancer, including HNC. Therefore, identification of SNPs, which serve as genetic susceptibility markers of tumors, has become a recent research interest. According to available evidence, SNPs in biotransformation enzymes (Shukla et al., [@B36]), DNA repair genes (Li et al., [@B21]), apoptotic pathways (Ma et al., [@B27]), alcohol metabolism (Bediaga et al., [@B2]), and immune inflammatory cytokines (Singh et al., [@B38]; Ma and Zhou, [@B28]) could affect the risk of HNC. Furthermore, these SNPs may also play a role in prognostication and may serve as a predictive tool in making treatment decisions for HNC (Zafereo et al., [@B42]; Lundberg et al., [@B26]; Sivadas et al., [@B39]; Zou et al., [@B44]).

Transforming growth factor beta 1 (TGF-β1) is a member of the transforming growth factor beta superfamily of cytokines. TGF-β1 can regulate both the immune system and cellular functions, including cell differentiation, cell proliferation, extracellular matrix production, apoptosis, and angiogenesis (Massagué, [@B29]). TGF-β1 also plays an important role in the carcinogenesis of various tumors. Genetic variations in the promoter region of the TGF-β1 gene may have an effect on transcription and protein synthesis. At present,−509C/T and 869T/C are the most commonly studied polymorphisms in TGF-β1. Recent studies have shown that SNPs of TGF-β1 are associated with susceptibility to a large range of cancers, including lung cancer (Fan et al., [@B12]), prostate cancer (Cai et al., [@B6]), gastric cancer (Chang et al., [@B10]), and hepatocellular cancer (Lu et al., [@B25]). Clinical studies have also been conducted to explore the association between SNPs in TGF-β1 and HNC susceptibility (Hu et al., [@B18]; Carneiro et al., [@B8]; Hsu et al., [@B17]; Khaali et al., [@B19]). However, findings are still inconclusive. Some results are even contradictory, particularly when the subjects are of the same ethnicity.

Considering that a single study, due to the small number of subjects, may be insufficient to provide a reliable conclusion, we performed a meta-analysis of all eligible studies in the hope of obtaining a more precise estimation of the association between the SNPs in TGF-β1 and a correlative HNC risk. The results of this meta-analysis may provide clinicians with better evidence-based evaluations and give patients guidance for early preventive care.

Materials and methods {#s2}
=====================

Literature search
-----------------

A comprehensive computer literature search was performed to identify studies on the association between gene polymorphisms of TGF-β1 and the risk of HNC. Embase and PubMed were searched on November 11, 2016 for eligible studies, with no restrictions on publication languages and dates. A combination of the following key words and Mesh terms was used: head and neck cancer; nasopharyngeal cancer; oral cancer; oropharyngeal cancer; laryngeal cancer; transforming growth factor; TGF; polymorphism. Additional studies were identified by a hand search of references of related studies and reviews.

Inclusion and exclusion criteria
--------------------------------

The studies must conform to the following criteria to be eligible: (1) they should be clinical studies focusing on the associations between TGF-β1 gene polymorphism and the risk of head and neck cancers; (2) the studies should provide sufficient data, including frequencies of alleles or genotypes in case and control groups to estimate the odds ratio (OR) value and 95% confidence interval (CI); (3) the cancer patients and control subjects are described and confirmed clearly in the studies; (4) the studies should use validated genotyping methods. The exclusion criteria were: (1) reviews or case reports, animal studies or introductory studies; (2) clinical studies not focused on the associations between TGF-β1 gene polymorphism and the risk of head and neck cancers; (3) studies with no available data reported, and duplicated reports.

According to the inclusion and exclusion criteria above, two reviewers (QS and XW) independently assessed potentially eligible studies. At first, irrelevant records were excluded after the titles and abstracts were examined, and then full-texts of potential interest were scanned. Any disagreement was resolved by discussing with a third reviewer (NH).

Data extraction
---------------

The following basic data were collected from the studies by two reviewers (QS and XW) independently: the first author, year of publication, design type of the study, ethnicity (Asian, Caucasian or other population), the type of cancer, description of study population (sample size, age, and sex), genotyping method, SNPs in each study, alleles or genotypes frequency, and the results of Hardy--Weinberg equilibrium (HWE).

Methodological assessment
-------------------------

To evaluate the quality of the included studies, a methodological quality assessment scale adjusted from previous publications (Camargo et al., [@B7]; Li et al., [@B22]) was adopted and assessed by two reviewers independently (CC and SY; Table [S1](#SM1){ref-type="supplementary-material"}). In the assessment scale, representativeness of cases, source of controls, sample size, quality control of genotyping methods, adjusted factors, and HWE results in the control subjects were used to appraise the methodological quality of the included studies. The scores of this scale range from 0 to 10, with 0 to 4, 5 to 7, and 8 to 10 indicating poor, moderate, and good study quality, respectively.

Statistical analyses
--------------------

Statistical analyses were performed using STATA software (Version 12.0; Stata Corp, College Station, Texas, USA). Pooled OR-value and 95%CI were calculated to evaluate the association between SNPs: −509C/T (rs18800469), 869T/C (rs1982073), and 915G/C (rs1800471) in TGF-β1 and HNC risk. Pooled ORs were performed for five models: allelic model (−509C/T: T vs. C; 869T/C: C vs. T; 915 G/C: C vs. G); homozygote model (−509C/T: TT vs. CC; 869T/C: CC vs. TT; 915 G/C: CC vs. GG); heterozygote model (−509C/T: TC vs. CC; 869T/C: CT vs. TT; 915 G/C: CG vs. GG); dominant model (−509C/T: TC/TT vs. CC; 869T/C: CT/CC vs. TT; 915 G/C: CG/CC vs. GG); and recessive model (−509C/T: TT vs. TC/CC; 869T/C: CC vs. CT/TT; 915 G/C: CC vs. CG/GG). Subgroup analyses were performed to explore whether particular characteristics in the studies (ethnicity, HWE, quality score) were related to the overall ORs and 95% CIs if there was a sufficient number of studies. HWE in each study was tested by Chi-square test. A *P*-value below 0.05 was considered statistically significant.

The statistical heterogeneity was verified by *I*^2^ statistics. If the *I*^2^-value was \<50%, it would suggest that the heterogeneity was low and a fixed-effect model was adopted to estimate the OR and 95%CI, otherwise, the random effects was used. Sensitivity analysis was made by removing one study each time in order to analyze the stability of the pooled results, if there were enough studies.

Results {#s3}
=======

Study selection and characteristics
-----------------------------------

A total of 163 records were identified after an initial search using Embase, PubMed and hand searching. After excluding duplicated records, 126 studies were left for screening. Of those, 113 articles obviously irrelevant to SNP in TGF-β1 gene and HNC risk were excluded after the titles and abstracts were read, leaving 13 articles for a further full-text review. Finally, 7 studies (Wei et al., [@B41]; Gaur et al., [@B13]; Al-Hadyan et al., [@B1]; Hu et al., [@B18]; Carneiro et al., [@B8]; Hsu et al., [@B17]; Khaali et al., [@B19]) were identified for this meta-analysis according to the inclusion criteria. The flow diagram of search processes and results of included studies are shown in Figure [1](#F1){ref-type="fig"}.

![Flow diagram for selection of studies. HNC, head and neck cancers.](fgene-08-00169-g0001){#F1}

All 7 included studies were case-control studies, and their publication dates ranged from 2007 to 2016. In total, 1534 cancer patients and 1744 control subjects were studied. Three studies (Wei et al., [@B41]; Hu et al., [@B18]; Khaali et al., [@B19]) reported on TGF-β1−509C/T polymorphism. Two of them focused on Asians populations (Wei et al., [@B41]; Hu et al., [@B18]), while the third one focused on North Africans (Khaali et al., [@B19]). Six studies (Wei et al., [@B41]; Gaur et al., [@B13]; Al-Hadyan et al., [@B1]; Hu et al., [@B18]; Carneiro et al., [@B8]; Khaali et al., [@B19]) reported on TGF-β1 869T/C polymorphism, four of which involved Asian subjects (Wei et al., [@B41]; Gaur et al., [@B13]; Al-Hadyan et al., [@B1]; Hu et al., [@B18]) and the other two involved Brazilians (Carneiro et al., [@B8]) and North Africans (Khaali et al., [@B19]). Two studies (Gaur et al., [@B13]; Hsu et al., [@B17]) reported on TGF-β1 915G/C polymorphism and both of them were conducted among Asians. The distribution of genotypes for the three SNPs in the controls of all studies was consistent with HWE, except for one study reporting on TGF-β1 869T/C (Carneiro et al., [@B8]). Six included studies (Wei et al., [@B41]; Gaur et al., [@B13]; Al-Hadyan et al., [@B1]; Hu et al., [@B18]; Hsu et al., [@B17]; Khaali et al., [@B19]) had a quality score ≥5 (moderate-high quality), while one study (Carneiro et al., [@B8]) had poor quality (the study deprived from HWE). All of the studies have reported that the study has been approved by the related committees. The general characteristics of the studies included in this meta-analysis are summarized in Table [1](#T1){ref-type="table"}.

###### 

Characteristics of studies included in the meta-analysis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author**   **Year**   **Country**    **Type of cancer**   **Case**    **Control**                             **Genotyping method**   **Adjusted factors**                    **SNP**    **HWE (*P*-value)**                          **Quality**               
  ------------------ ---------- -------------- -------------------- ----------- --------------------------------------- ----------------------- --------------------------------------- ---------- -------------------------------------------- ------------- ----------- ---
  Khaali W           2016       Morocco        NPC                  384\        42.24[^a^](#TN1){ref-type="table-fn"}   361\                    43.58[^a^](#TN1){ref-type="table-fn"}   PCR-RFLP   Sex, age household in childhood              −509 C/T\     0.92 0.61   8
                                                                    (263/121)                                           (243/118)                                                                                                               869 T/C                   

  Hsu HJ             2015       China          OC                   162\        52.70 ± 12.38                           128\                    59.20 ± 12.91                           PCR-SSP    Age, smoking, drinking, betel quid chewing   915 G/C       0.18        7
                                                                    (125/37)                                            (77/51)                                                                                                                                           

  Carneiro NK        2013       Brazil         OC                   62\         57.26 ± 11.30                           62\                     43.44 ± 11.09                           PCR        ---                                          869 T/C       0.01        4
                                                                    (62/0)                                              (62/0)                                                                                                                                            

  Hu S               2012       China          NPC                  522\        46[^b^](#TN2){ref-type="table-fn"}      712\                    47[^b^](#TN2){ref-type="table-fn"}      PCR-RFLP   Age, sex                                     −509 C/T\     0.39 0.99   7
                                                                    (315/207)                                           (404/308)                                                                                                               869 T/C                   

  Al-Hadyan KS       2012       Saudi Arabia   Mixed                156\        50[^b^](#TN2){ref-type="table-fn"}      251\                    47[^b^](#TN2){ref-type="table-fn"}      PCR        ---                                          869 T/C       0.92        5
                                                                    (122/34)                                            (191/60)                                                                                                                                          

  Gaur P             2011       India          OC                   140\        51.4 ± 13.6                             120\                    NR                                      PCR-RFLP   Age, sex, ethnicity                          869 T/C\      0.29 0.20   8
                                                                    (119/21)                                            (NR)                                                                                                                    915 G/C                   

  Wei YS             2007       China          NPC                  108\        49.8 ± 10.5                             120\                    48.3 ± 11.2                             PCR-RFLP   Age, sex, smoking status                     −509 C/T\     1 0.98      7
                                                                    (76/32)                                             (82/38)                                                                                                                 869 T/C                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*SNP, single nucleotide polymorphism; HWE, Hardy--Weinberg equilibrium; NPC, nasopharyngeal carcinoma; OC, oral cancer; PCR-RFLP, polymerase chain reaction restriction fragment length polymorphism; PCR-SSP, polymerase chain reaction sequence-specific primer; NR, not report*.

*The mean age of the subjects*.

*The median age of the subjects*.

Meta-analysis results
---------------------

### −509C/T

The meta-analysis of TGF-β1−509C/T polymorphism was based on 3 studies (Wei et al., [@B41]; Hu et al., [@B18]; Khaali et al., [@B19]). Because the statistical heterogeneity between them was high (all *I*^2^-values were more than 50%), the random effects model was applied. Overall, this meta-analysis failed to identify a significant association between TGF-β1−509C/T polymorphism and HNC risk in terms of both allele frequency and genotype distribution (T vs. C: OR = 0.954, 95%CI: 0.612--1.488, *P* = 0.837; TT vs. CC: OR = 0.882, 95%CI: 0.388--2.007, *P* = 0.765; TC vs. CC: OR = 0.864, 95%CI: 0.591--1.262, *P* = 0.449; TC/TT vs. CC: OR = 0.894, 95%CI: 0.539--1.483, *P* = 0.663; TT vs. TC/CC: OR = 0.930, 95%CI: 0.478--1.811, *P* = 0.832; Figure [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Furthermore, subgroup analysis based on ethnicity showed no significant association in TGF-β1−509C/T polymorphism and HNC risk between Asian groups and other populations.

![Forest plot of the TGF-β1−509C/T polymorphism and HNC risk in all comparison models. OR, odds ratio, CI, confidence interval.](fgene-08-00169-g0002){#F2}

###### 

Statistics for polled ORs and subgroup analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Subgroup**                                  **OR**\              ***P*-value**   ***I*^2^**\     **OR**\              ***P*-value**      ***I*^2^**\   **OR**\           ***P*-value**   ***I*^2^**\   **OR**\              ***P*-value**   ***I*^2^**\   **OR**\          ***P*-value**   ***I*^2^**\
                                                **(95%CI)**                          **(%)**         **(95%CI)**                             **(%)**       **(95%CI)**                       **(%)**       **(95%CI)**                          **(%)**       **(95%CI)**                      **(%)**
  ----------------------------------------- --- -------------------- --------------- --------------- -------------------- ------------------ ------------- ----------------- --------------- ------------- -------------------- --------------- ------------- ---------------- --------------- -------------
  −**509 C/T**                                  **T vs. C**          **TT vs. CC**   **TC vs. CC**   **TC/TT vs. CC**     **TT vs. TC/CC**                                                                                                                                                     

  Total                                     3   0.954\               0.837           90.3            0.882\               0.765              88.2          0.864\            0.449           65.0          0.894\               0.663           82.6          0.930\           0.832           86.9
                                                (0.612--1.488)                                       (0.388--2.007)                                        (0.591--1.262)                                  (0.539--1.483)                                     (0.478--1.811)                   

  Asians                                    2   1.021\               0.964           94.9            1.023\               0.978              93.9          0.849\            0.631           69.7          0.952\               0.926           88.7          1.067\           0.918           93.5
                                                (0.414--2.516)                                       (0.194--5.392)                                        (0.435--1.656)                                  (0.333--2.716)                                     (0.310--3.665)                   

  Others [^a^](#TN3){ref-type="table-fn"}   1   0.884\               0.279           --              0.742\               0.211              --            0.977\            0.891           --            0.912\               0.571           --            0.752\           0.193           --
                                                (0.707--1.105)                                       (0.465--1.184)                                        (0.698--1.368)                                  (0.664--1.253)                                     (0.490--1.155)                   

  **869 T/C**                                   **C vs. T**          **CC vs. TT**   **CT vs. TT**   **CT/CC vs. TT**     **CC vs. CT/TT**                                                                                                                                                     

  Total                                     6   **1.351**\           **0.030**       80.1            **1.585**\           **0.038**          71.8          1.279\            0.097           56.0          **1.398**\           **0.044**       69.9          1.314\           0.095           62.5
                                                **(1.030--1.772)**                                   **(1.026--2.449)**                                    (0.957--1.709)                                  **(1.008--1.937)**                                 (0.953--1.810)                   

  Asians                                    4   **1.400**\           **0.048**       83.1            **1.814**\           **0.043**          75.6          1.184\            0.115           49.4          1.435\               0.083           71.3          1.588\           0.050           70.5
                                                **(1.003--1.956)**                                   **(1.018--3.233)**                                    (0.963--1.455)                                  (0.953--2.159)                                     (1.000--2.428)                   

  Others[^a^](#TN3){ref-type="table-fn"}    2   1.48\                0.46            83.4            1.282\               0.606              71.4          1.643\            0.388           81.5          1.502\               0.434           81.5          0.916\           0.611           0
                                                (0.52--4.19)                                         (0.498--3.299)                                        (0.532--5.073)                                  (0.542--4.166)                                     (0.653--1.285)                   

  HWE[^b^](#TN4){ref-type="table-fn"}       5   1.273\               0.075           80.8            1.514\               0.083              75.2          1.129\            0.175           39.8          1.290\               0.117           68.7          1.350\           0.107           70.0
                                                (0.976--1.660)                                       (0.947--2.420)                                        (0.948--1.345)                                  (0.938--1.774)                                     (0.937--1.946)                   

  **915 G/C**                                   **C vs. G**          **CC vs. GG**   **CG vs. GG**   **CG/CC vs. GG**     **CC vs. CG/GG**                                                                                                                                                     

  Total                                     2   3.094\               0.180           94.5            1.584\               0.188              0             4.15\             0.200           95.3          4.021\               0.173           95.0          1.327\           0.387           5.5
                                                (0.594--16.119)                                      (0.799--3.141)                                        (0.470--36.682)                                 (0.544--29.733)                                    (0.699--2.517)                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*N, Number of studies; OR, Odds ratio; CI, Confidence interval; P, P-values for pooled ORs; HWE, Hardy--Weinberg equilibrium*.

*Other ethnicity*.

*The studies in which Hardy--Weinberg equilibrium in control subjects*.

*The bold values indicate the results of the analysis in these models are of statistical significant*.

### 869T/C

Meta-analysis of the ORs between TGF-β1 869C/T polymorphism and HNC risk was performed in six included studies (Wei et al., [@B41]; Gaur et al., [@B13]; Al-Hadyan et al., [@B1]; Hu et al., [@B18]; Carneiro et al., [@B8]; Khaali et al., [@B19]). Significant associations were observed in the allelic model (C vs. T: OR = 1.351, 95%CI: 1.030--1.772, *P* = 0.030), homozygote model (CC vs. TT: OR = 1.585, 95%CI: 1.026--2.449, *P* = 0.038), and dominant model (CT/CC vs. TT: OR = 1.398, 95%CI: 1.008--1.937, *P* = 0.044), as shown in Figure [3](#F3){ref-type="fig"} and Table [2](#T2){ref-type="table"}. However, no significant association was found in the heterozygote model (CT vs. TT: OR = 1.279, 95%CI: 0.957--1.709, *P* = 0.097) and recessive model (CC vs. CT/TT: OR = 1.314, 95%CI: 0.953--1.810, *P* = 0.095). The random effects model was applied in the comparisons due to high statistical heterogeneity. In this SNP, sensitivity analysis was performed by sequentially removing one study each time. As shown in the Table [S2](#SM2){ref-type="supplementary-material"}, the results of the pooled OR were robust only in the CT vs. TT model, but were not stable in the comparison of the four models: C vs. T, CC vs. TT, CT/CC vs. TT, and CC vs. CT/TT.

![Forest plot of the TGF-β1 869T/C and HNC risk in all comparison models. OR, odds ratio, CI, confidence interval.](fgene-08-00169-g0003){#F3}

In subgroup analysis, a significant association was observed in the Asian group using the allelic model (C vs. T: OR = 1.400, 95%CI: 1.003--1.956, *P* = 0.048) and the homozygote model (CC vs. TT: OR = 1.814, 95%CI: 1.018--3.233, *P* = 0.043), while there was no significant association in other populations. After removing the study derived from HWE (also the low-quality study; Carneiro et al., [@B8]), no significant association was found in the overall comparison. The results of subgroup analyses are shown in Table [2](#T2){ref-type="table"}.

### 915G/C

Two studies (Wei et al., [@B41]; Hsu et al., [@B17]) reported on TGF-β1 915G/C polymorphism and HNC risk. No significant association was observed in the overall comparison (C vs. G: OR = 3.094, 95%CI: 0.594--16.119, *P* = 0.180; CC vs. GG: OR = 1.584, 95%CI: 0.799--3.141, *P* = 0.188; CG vs. GG: OR = 4.15, 95%CI: 0.470--36.682, *P* = 0.200; CG/CC vs. GG: OR = 4.021, 95%CI: 0.544--29.733, *P* = 0.173; CC vs. CG/GG: OR = 1.327, 95%CI: 0.699--2.517, *P* = 0.387; Figure [4](#F4){ref-type="fig"} and Table [2](#T2){ref-type="table"}). The fixed effect model was applied in the homozygote model and recessive model because the *I*^2^-values were \<50%. However, no subgroup analysis was performed due to the limited number of studies.

![Forest plot of the TGF-β1 915G/C and HNC risk in all comparison models. OR, odds ratio, CI, confidence interval.](fgene-08-00169-g0004){#F4}

Discussion {#s4}
==========

Inflammation, and expression of relevant cytokines, are important in the promotion, occurrence, and development of HNC. As a multifunctional cytokine, TGF-β1 plays a biphasic role in carcinogenesis. In the early stages, TGF-β1 acts as a cancer inhibitor by regulating epithelial cell proliferation, differentiation, and apoptosis (Rich et al., [@B34]; Siegel and Massagué, [@B37]). However, in the advanced and late stages, it acts as a cancer promoter by promoting epithelial to mesenchymal transition, enhancing metalloproteases expression, and increasing cancer motility and angiogenesis (Siegel and Massagué, [@B37]; Tang et al., [@B40]). In addition, TGF-β1 may contribute to the aggressive behavior of cancers through the local and systemic immunosuppression effect (Tang et al., [@B40]). Therefore, the SNPs in TGF-β1 will alter the level of protein expression, which may affect the susceptibility to some diseases, including HNC.

It has been reported that elevated levels of TGF-β1 mRNA and functional protein were identified in the stromal compartment of HNC both *in vitro* and *in vivo* compared with normal tissues, suggesting that TGF-β1 overexpression may provide an HNC promoting microenvironment (Lu et al., [@B24]; Rosenthal et al., [@B35]). Though there are studies showing that the C allele in −509C/T polymorphism could increase the level of TGF-β1 expression in serum and in nasopharyngeal carcinoma (NPC) cell lines (Hu et al., [@B18]), our meta-analysis failed to identify a significant association between TGF-β1−509C/T polymorphism and HNC risk in all of the alleles or genotype models. The same results were also found in the subgroup analysis stratified by ethnicity. The pooled ORs and 95%CIs indicated that TGF-β1−509C/T polymorphism may not affect susceptibility to HNC, but this result should be treated with some caution due to the limited number of included studies focusing on this SNP and high statistical heterogeneity. The conclusions of these three studies are not consistent. Khaali et al. found that in the North African sample, the TGF-β1−509C/T polymorphisms did not substantially influence HNC susceptibility (Khaali et al., [@B19]). However, the conclusions of the other two studies on Asian samples were the opposite: one concluded the−509T allele carriers were associated with a significantly reduced risk of HNC (Hu et al., [@B18]), while the other suggested the T allele increased the HNC risk (Wei et al., [@B41]). Previous studies on the TGF-β1−509C/T polymorphism and risk of cancers were also inconsistent. It has been reported that there was no significant association between the TGF-β1−509C/T polymorphism and risk of gastric cancer (Niu et al., [@B32]) and breast cancer (Lu et al., [@B24]). However, based on a meta-analysis of 55 case-control studies, Liu et al. suggested that TGF-β1−509C/T polymorphism might contribute to a decreased risk of colorectal cancer susceptibility, while no association with other cancer risk was identified (Liu et al., [@B23]). Therefore, the influence of this SNP on cancers may vary from cancer to cancer.

Small but statistically significant associations were observed in the allelic model (C vs. T: OR = 1.351, 95%CI: 1.030--1.772, *P* = 0.030), homozygote model (CC vs. TT: OR = 1.585, 95%CI: 1.026--2.449, *P* = 0.038), and dominant model (CT/CC vs. TT: OR = 1.398, 95%CI: 1.008--1.937, *P* = 0.044) of TGF-β1 869C/T polymorphism. These data indicate that the C allele and the CC genotype may increase the risk of HNC. This may be associated with an increased TGF-β1 level in carriers of the C allele, which might lead to a slightly attenuated immune function and further increase of risk in developing HNC. These findings were similar to those of the two previous meta-analyses. One meta-analysis found weaker evidence for TGF-β1 869C/T polymorphism and breast cancer risk (Cox et al., [@B11]), while the other, based on 31 studies, conducted a subgroup analysis to explore the association between 869C/T polymorphisms and HNC risk. This study found that this SNP was associated with increased risk of HNC (TC vs. TT: OR = 1.34, 95%CI: 1.07--1.67; Gu et al., [@B15]). Conversely, another study showed that the C allele was found to be associated with decreased risk of hepatocellular cancer (Zhang et al., [@B43]). However, the subgroup analysis in our study found that these overall results may be affected by ethnicity and HWE. Significant association was observed in Asian groups in the allelic model (C vs. T: OR = 1.400, 95%CI: 1.003--1.956, *P* = 0.048) and the homozygote model (CC vs. TT: CC vs. TT: OR = 1.814, 95%CI: 1.018--3.233, *P* = 0.043), while there was no significant association in other populations. After we removed the study derived from HWE, no significant association was found in the overall comparison. Sensitivity analysis performed by sequentially removing one study each time showed that the results of the pooled OR were robust only in the CT vs. TT model, but were not stable in four models: C vs. T, CC vs. TT, CT/CC vs. TT, and CC vs. CT/TT. This instability may be caused by three factors: first, the limited number of the included studies; second, a strong SNP effect with a large 95%CI caused by the small sample size of some included studies; and third, different race and the adjusted confounded factors in the included studies. Therefore, more well-designed studies with larger sample sizes are needed to validate our meta-analysis.

Regarding TGF-β1 915G/C polymorphism, no significant association was observed in all of the comparison models. Only two included studies reported on TGF-β1 915G/C polymorphism and both involved Asian populations, hence no subgroup analysis was conducted. The conclusions of these two studies are also inconsistent. Guar et al. found that 915G/C SNP did not show any significant difference in genotype and allele frequencies between patients and controls (Gaur et al., [@B13]), while Hsu et al. concluded that the C allele and the GC genotype of TGF-β1 was significantly higher in frequency in cancer patients compared with a healthy control group (Hsu et al., [@B17]). In a previous study, Niu et al. also found that there was no significant association between 915G/C polymorphisms and the risk of gastric cancer, both in overall analyses and subgroup analyses based on ethnicity (Niu et al., [@B32]).

In this meta-analysis, the statistical heterogeneity was high in most of the comparison models and the subgroup analyses. Three factors may contribute to the high heterogeneity. First, environmental factors are of importance in the development of cancers, hence well-matched control subjects in a case-control study may produce more reliable results. However, all seven included studies were case-control studies that adjusted different number and kind of confounding factors. This may profoundly affect the accuracy of the results and increase the heterogeneity between the studies. Second, the role of genetic factors may vary in different ethnicities. The findings of the studies on different races may be different, which will increase the heterogeneity between the included studies. Third, the number of studies included in this meta-analysis is limited, especially concerning the TGF-β1−509C/T and 915G/C polymorphism. Moreover, the sample size in the included studies is also limited.

Previously there was a meta-analysis assessing the association in a subgroup analysis, but the authors included only four studies on HNC (Gu et al., [@B15]). Therefore, to the best of our knowledge, this is the most comprehensive meta-analysis to estimate the association between SNPs in TGF-β1 and HNC risk. In addition, subgroup analyses were performed to explore whether particular characteristics of studies were related to the overall analysis. Nevertheless, there are some limitations that should be addressed. First, one study with low quality or derived from HWE, was included; however, this study was removed when the subgroup analysis was performed. Second, due to the limited number of studies, the publication biases of the included studies have not been analyzed. Third, the studies on−509C/T, 915G/C and the non-Asian population (classified as "others" in this study) are limited, so the related results should be treated with some caution. Fourth, the pooled ORs in the 869T/C were not stable and more studies are needed.

In summary, our meta-analysis indicated that there was no statistical association between TGF-β1−509C/T, 915G/C polymorphism and HNC risk in any genetic models, but we found that TGF-β1 869C/T polymorphism may be involved in the susceptibility to HNC, especially in Asian patients. However, considering the limitations of this study, the results should be interpreted with some caution. More well-designed studies with larger sample sizes and well-matched controls are required to validate our conclusion, especially concerning non-Asian populations.
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